{"name":"Neomorph, Inc","slug":"neomorph-inc","ticker":"","exchange":"","domain":"neomorph.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUGdIS0toTU9xdnJQOEJKTFBrUEdGMlF3RGRIVDVaS2g5a3NMcUVuR085aUhpNTJXLUFUbGxmS3JUVkJEMVlIOWEwRDVFVTNnUUVjbmJJS0gtc0dtdlBDZW12eDMwdHExa09wUVpiekotdGw1TV9EU09xdFdwQlNCRm1KeUVaZV9tVXV6SU1IcDBCc0oyc0FHcy1UQ1Mzb3FkLXRHVlhkYTJqcVpwQUpiZVRrbVFrclJuQU9XMnVSRlJ6RWFUR09RU080akFZNjU3aFV3OTZXMEVHLUE?oc=5","date":"2026-02-03","type":"pipeline","source":"San Diego Union-Tribune","summary":"‘Molecular glue’ from this San Diego startup makes cancer self-destruct; Big Pharma bets billions - San Diego Union-Tribune","headline":"‘Molecular glue’ from this San Diego startup makes cancer self-destruct; Big Pharma bets billions - San Diego Union","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcEdMRDdrVU9YeTE4QVFiN0J3LTB1M052UzlkZ0JCLTlYTDBsVEFMNWxPVkxoVWRsc0VzdnIxdXRpejh3anhzXzREOHRwNDRoTzdlU01FRW5rUWZjbmRXUFByVmZKSjFxZ0RwdVktWnNzOXRIT3lCYTR6Z1oxTEQzUEVDV250akk2NmRMNm9qZFdja3l3b1dJSldILXpvUG9KaTVzS01RUzFJZ3Y5MWo0bmJ5YkpzQQ?oc=5","date":"2025-05-21","type":"pipeline","source":"BioSpace","summary":"Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space - BioSpace","headline":"Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOVXJhLXo5b3hwWEVocldqRXVISDM1NkhlVk5LVmZrN0ZTZTlUT2Z3Yk0tN2tLX3hQaVBod0Z5VnFkLUxaNllaWHlzdUw1VlVXZjBIQUd0eTgtcWNTVWFwZVdlcDFqSGgxYkZxVUJHbnFpQ2x4T210NS1lc2tvV1NrcHJIdnViUVhQRTF1Uw?oc=5","date":"2025-02-03","type":"pipeline","source":"San Diego Business Journal","summary":"Neomorph, AbbVie Ink $1.64B Collab - San Diego Business Journal","headline":"Neomorph, AbbVie Ink $1.64B Collab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPbGlKMzhRb3FKc1h4Rm42SnJyS3JZSVJHaDYwSnh5TkxQemVhbEVydXcwQVVLSkMyYVRNdE1jU3QtRUk0NDl1RDR2TXpmcXdTSFZ4Sm55aG5TOHAzNkVqclYxM09kNGZxRXpaNWl0MnJMNVR5MUU0bEFwMEpiY0o3WG1fVTlQZWFtVm85eHZ3ejBRb2xhcjhfcjhUUVdOaE1JNm00RHFSRjVOZS1LRnZqT0dvNA?oc=5","date":"2025-01-23","type":"deal","source":"Fierce Biotech","summary":"Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact - Fierce Biotech","headline":"Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVXFCdF9MLXlyUGM5T1NtRFRnLUZHRUZDbE9GNE9fdzFNeEJndHZXLUlGempTM3hoS2hiNmtjOFBrZ3RKdDhTQkFuZ2pYY3lnLW5sb212MnBtMXNGLW1GcWNXbWtBVGxNbzFadThXUWE5czVJX2NKNl9LTjNtd1R2STJ0VXltZmgxczVndDdhS2R5OTdESFJNdnBYY0sxOF9xQUJBa3YzbEs?oc=5","date":"2024-12-16","type":"pipeline","source":"BioSpace","summary":"Molecular Glue Degraders at Inflection Point as Pharma Dives In - BioSpace","headline":"Molecular Glue Degraders at Inflection Point as Pharma Dives In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNVi04dnc2TURIdU04MmtSam5abEhOeGlaWjFRd2FLeThBMXBLOW05LUxUNzNlMll6enBqYkhLTndKMkRxTzVuZjFVM3p6cXR3TmFFY2JSNUwxNFlBMzFVN0ZGa0JxcHRBT3Fva082eXExRnNnRkNhUEo4dTFyTEE5X2xUZnNTQWRqY3JLUE9XTjBmNk9GMzFXSUREeWxDRDZBM3Iw?oc=5","date":"2024-10-31","type":"pipeline","source":"BioWorld News","summary":"Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld News","headline":"Biogen, Neomorph pact worth $1.45B for molecular glue degraders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOeDJIQ2cteGRJZGpzb2xEVTY2Z0I0Y09xTnhvaGhfNDRFanBoal94eFlDYTZ4UC1uUGt3MHBaM01rUDlWLTE4STJWZWFqU0VaN29ENDhIc1J4WklMa0Fya0J5MmtHNXJJVl9jN1ZKdVRydW1tQ1hFUDdjQW8yZXJwT2V1U0h3el9nWDNrUko4OV9lbmY3RkxQWkpNSG1IQjhXTVE0MndR?oc=5","date":"2024-02-27","type":"deal","source":"Contract Pharma","summary":"Neomorph, Novo Nordisk Partner on Molecular Glue Degraders - Contract Pharma","headline":"Neomorph, Novo Nordisk Partner on Molecular Glue Degraders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbEI3SGFjb0wtS180VkpsM3Y2SHVycDFjdElQRWhlY0tSZkgwb3Z0NlVraVVBT3lSajI3X0VsR1VkaENsbHFoaE1LeEZYWWpFNkdRM2ZMaVlLUTNxUlN4VlR1Y3lIRXFNSG1zX0JIaFpmZHNkcV8zSEI1QloxcHBfSmlWb05rNFpicW5ObmtfeElKdFJvUVBlNVdQVnZybVlYY0tISGk3MnhwSk1KM2daZTA5UHN0WVIxeFcw?oc=5","date":"2022-09-07","type":"pipeline","source":"Business Wire","summary":"Neomorph, Inc. Announces Appointment of Chief Financial Officer - Business Wire","headline":"Neomorph, Inc. Announces Appointment of Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPRDZzc0Z4bnBkTEZ4bWJRQXY3WGlTWUJaRFp0RG44VUozMGtRYWtlTE92NG9aTnBMZ1BUQUowMUVxSTVmY2xySF9kaUdiYXRfZlBJZnJ5MFVDWTNzU1lsZlV6TmRiUUpxZ1F3S1hZSXk4MDVyUktyRlRuU282Y0JwUFVrcEhuUEFidUI1d1BmOERWVG9Wa19xOUo4WmpKRkZqMUdDSmZYY3RUQTJhdHUwUWkxWkJaaTdzODQybEI1VUJvbHRTVDdJeTNlTWFGNUcwRFFPNHphU2NqS0IxWmtsc2JhS2RibVdsSUREMVQxLWlkU3FpZ1hyRWR5MkRDRTFJSmNpUkl6aGwtQXc?oc=5","date":"2020-12-22","type":"pipeline","source":"Business Wire","summary":"Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs - Business Wire","headline":"Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Program","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}